Vivos Therapeutics Inc. (VVOS): Price and Financial Metrics


Vivos Therapeutics Inc. (VVOS): $0.40

-0.01 (-1.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VVOS Stock Summary

  • VIVOS THERAPEUTICS INC's market capitalization of $10,424,490 is ahead of merely 3.65% of US-listed equities.
  • With a one year PEG ratio of 0.54, VIVOS THERAPEUTICS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.96% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VVOS comes in at -267.93% -- higher than that of merely 2.16% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to VIVOS THERAPEUTICS INC, a group of peers worth examining would be BIRD, CURI, MBUU, BTTR, and OXBR.
  • Visit VVOS's SEC page to see the company's official filings. To visit the company's web site, go to www.vivoslife.com.

VVOS Valuation Summary

  • In comparison to the median Healthcare stock, VVOS's EV/EBIT ratio is 97.7% lower, now standing at 0.2.
  • VVOS's price/earnings ratio has moved up 12.9 over the prior 24 months.

Below are key valuation metrics over time for VVOS.

Stock Date P/S P/B P/E EV/EBIT
VVOS 2022-12-02 0.6 0.5 -0.5 0.2
VVOS 2022-12-01 0.7 0.5 -0.5 0.2
VVOS 2022-11-30 0.7 0.5 -0.5 0.2
VVOS 2022-11-29 0.7 0.6 -0.5 0.2
VVOS 2022-11-28 0.8 0.6 -0.6 0.1
VVOS 2022-11-25 0.8 0.7 -0.6 0.1

VVOS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VVOS has a Quality Grade of D, ranking ahead of 23.33% of graded US stocks.
  • VVOS's asset turnover comes in at 0.795 -- ranking 38th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows VVOS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.795 0.797 5.192
2020-12-31 0.795 0.797 5.192

VVOS Price Target

For more insight on analysts targets of VVOS, see our VVOS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.00 Average Broker Recommendation 1.5 (Moderate Buy)

VVOS Stock Price Chart Interactive Chart >

Price chart for VVOS

VVOS Price/Volume Stats

Current price $0.40 52-week high $3.69
Prev. close $0.41 52-week low $0.37
Day low $0.37 Volume 57,978
Day high $0.43 Avg. volume 618,896
50-day MA $0.65 Dividend yield N/A
200-day MA $1.45 Market Cap 9.20M

Vivos Therapeutics Inc. (VVOS) Company Bio


Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integrated Healthcare Network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate OSA. Vivos Therapeutics, Inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals. It caters to general dentists, medical doctors, myofunctional therapists, chiropractors, healthcare providers, and patients in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2007 and is based in Highlands Ranch, Colorado.


VVOS Latest News Stream


Event/Time News Detail
Loading, please wait...

VVOS Latest Social Stream


Loading social stream, please wait...

View Full VVOS Social Stream

Latest VVOS News From Around the Web

Below are the latest news stories about VIVOS THERAPEUTICS INC that investors may wish to consider to help them evaluate VVOS as an investment opportunity.

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q

Vivos expects to become current on its SEC filings in the coming weeksLITTLETON, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Quarterly Report on Form 1

Yahoo | November 28, 2022

Vivos Therapeutics First Quarter 2022 Earnings: Revenues Disappoint

Vivos Therapeutics ( NASDAQ:VVOS ) First Quarter 2022 Results Key Financial Results Revenue: US$3.46m (flat on 1Q...

Yahoo | November 27, 2022

Vivos Therapeutics Provides Update on Revenue Recognition Review

Detailed Analysis Finds Minimal Impact on Prior Financial Results;No Previously Reported Revenue to be Lost Previously Reported First Quarter 2022 Revenue Expected to Increase Approximately $200,000; No Need to Restate Prior Year Financial Statements Restated First Quarter 2022 Results to be Filed Shortly;Second and Third Quarter 2022 Financial Results Expected By Year End HIGHLANDS RANCH, Colo., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS

Yahoo | November 22, 2022

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

LITTLETON, Colo., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the “Form 10-Q”). Such a noti

Yahoo | August 26, 2022

Vivos Therapeutics Provides Update on Second Quarter Earnings Delay

Delay Due to Technical Revenue Recognition Analysis and Unrelated to Overall Business HealthLITTLETON, Colo., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos”) is providing an update on the delay in announcing its second quarter 2022 financial results. “We are disappointed it is taking longer than usual to report our financial and operating results for the second quarter,” stated Kirk Huntsman, Chairman and CEO of Vivos. “Importantly, we want to provide assuranc

Yahoo | August 22, 2022

Read More 'VVOS' Stories Here

VVOS Price Returns

1-mo -39.18%
3-mo -66.10%
6-mo -73.51%
1-year -83.87%
3-year N/A
5-year N/A
YTD -82.22%
2021 -61.93%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7512 seconds.